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ABSTRACT 
Objective: Rising cost of medical therapy is a major concern for patients, and there is high variability in the prices of numerous branded medicines 
available in India. Drug Price Control Order (DPCO) 2013 was implemented by the government of India with the aim of bringing down the cost of 
essential medicines. This cost analysis study was carried out to assess the brand price variation in major classes of common drugs under price 
control; thus assessing the impact of DPCO and analyse issues related to it.  
Methods: Latest price list of available brands for cardiovascular drugs, antibacterial, analgesics, drugs for diabetes, asthma, arthritis, convulsions 
covered under the DPCO, was procured from a leading commercial drug directory. Unit prices of drug formulations available as different brands 
were compared. Maximum-minimum prices and average prices were found. Price variations between brands were calculated and expressed as 
percentage variations. Assessment of existing pricing policy and quality norms was done.  
Results: Significant inter-brand price variations were found for the majority of formulations. These variations ranged from more than 100 % from 
average to more than 500 % between maximum and minimum brand prices for drugs like amlodipine, atorvastatin, diclofenac, amoxicillin-
clavulanic acid, clopidogrel. Out of 60 formulations observed, 40 showed price variations in excess of 50 % from average price and 23 showed 
variations greater than 200 % between the costliest and cheapest brands.  
Conclusion: Despite the implementation of price control, brand price variations still exist widely for commonly used drugs. Re-assessment of 
pricing policy and implementation of quality norms is needed.  
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INTRODUCTION 
Pricing of medicines is a very sensitive issue for a developing 
country like India. It has direct economic implications on patients 
and plays a significant role in determining compliance to treatment; 
the plethora of brands available in India for the majority of drugs 
further complicates this problem [1]. To ensure that vital drugs are 
available at the affordable prices, the government of India exercises 
control over the prices of certain drugs defined as ‘essential’ through an 
order called Drugs (Prices Control) Order commonly referred to as the 
DPCO. The current DPCO became effective in May 2013 [2]. The National 
Pharmaceutical Pricing Authority (NPPA) implements this DPCO [3]. The 
National List of Essential Medicines (NLEM) is a list of medicines 
prepared by the Ministry of Health and Family Welfare, which satisfy the 
health care needs of the majority of the population [4].  
Under the provisions of DPCO 2013, prices of the 348 drugs in NLEM 
2011 are monitored and controlled by the NPPA [2]. Only 74 drugs 
were subjected to price control in the previous DPCO 1995 [5]. As 
per the compendium of ceiling prices published in 2015, effective 
from 1st April, the NPPA had fixed ceiling prices of 509 formulations 
out of a total of 628 net formulations to be covered under the DPCO. 
This has increased with subsequent notifications [3, 6-8].“Ceiling 
price" means a price fixed by the government in accordance with the 
provisions of the DPCO [2]. 
This price control has come under scrutiny recently, with the 
Supreme Court of India calling the pricing policy as "unreasonable 
and irrational", and asking the government to re-examine it [9]. The 
DPCO had also come heavily under the scanner for bringing an 
additional 108 non-scheduled formulations under price control in 
the public interest, [10] then withdrawing its decision [11].  
Multiple brands are available for a single drug in India and variations 
are known to be prevalent in the prices of these brands because an 
open competitive market system entertaining both domestic and 
foreign manufacturers is followed [12]. With the implementation of 
price control, such price variations are expected to have come down. 
The DPCO states that reducing such inter-brand price variations in 
major therapeutic groups is one of its major aims [13].  
‘Cost analysis’ is a type of partial pharmacoeconomic evaluation which 
compares the costs of two or more alternatives without regard to 
outcome [14, 15]. Different brands of the same drug are the 
alternatives available for a patient, expected to provide a same 
therapeutic outcome. Analysis of their costs can highlight the 
phenomenon of ‘inter-brand price variation’ which can put the 
substantial financial burden on patients along with posing moral and 
ethical concerns. 
Few previously conducted studies have shown that there is indeed a 
wide variation in brand prices in the Indian market, but the data is 
still scant, and these studies focused on drugs in a single therapeutic 
area [16-18]. Assessing brand price variation of essential drugs 
under price control across multiple therapeutic areas would give a 
much better assessment of the actual state of price variations and 
the impact of current drug pricing policy.  
Drugs for treatment of cardiovascular disorders like hypertension, 
heart failure, Myocardial Infarction (MI), bacterial infections 
including tuberculosis-leprosy, diabetes, asthma, epilepsy, arthritis, 
pain can be considered as some of the most commonly used drugs. 
Hence, these drug groups were chosen for cost analysis in this study.  
MATERIALS AND METHODS 
Current Index of Medical Specialities-CIMS (July–October 2015 
edition, India) was referred to for dosage and prices of the different 
brands of the aforementioned groups of drugs. CIMS is considered a 
trusted and authentic source of commercial drug information and 
was chosen as the single source of information to ensure uniformity 
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of price data, and avoid repetition and ambiguity which may arise 
from using multiple sources. The average price was calculated by 
adding up the prices of different brands for a particular drug and 
dividing the sum by a total number of brands. Price variation 
calculations for drug formulations having a minimum of five 
available brands were included in the final observation as it was 
deemed unjustified to comment on price variations with less than 
five brands. The (single) unit prices for all oral formulations and 
injections were taken, as the DPCO also fixes ceiling prices for one unit. 
Special formulations like extended release/dispersible tab/controlled 
release etc. were excluded. The ceiling prices that have been notified in 
the compendium of notified ceiling prices 2015 were noted.  
Following parameters were noted/calculated:  
1. Retail unit prices of the different brands of the same drug 
formulations. 
2. A number of brands available for a drug formulation. 
3. The average price of each formulation. 
4. Maximum and minimum prices for each formulation. 
5. Percentage deviation of maximum and minimum prices from the 
average price: [17] 
 
 
6. Percentage variation between maximum and minimum prices: [15]  
 
RESULTS 
Out of the 27 therapeutic areas in the NLEM brought under price 
control through DPCO 2013, we looked up the brands and prices 
available for drugs from six therapeutic areas (Cardiovascular drugs, 
anti bacterials, analgesics-anti-inflammatories, antidiabetic, 
antiasthma, anticonvulsants, anti-arthritis drugs) in CIMS. We could 
find 36 drugs and their 60 different dose formulations from the 
above categories of drugs. Among the drugs used for cardiovascular 
diseases [table 1], we observed 10 drugs in 17 formulations. All 
formulations, except three, showed more than 100 % variation 
between maximum and minimum priced brands. Five formulations 
showed more than 500 % variation; largest with Clopidogrel 75 mg 
tablet (1067.5 %) followed by amlodipine 5 mg tab (1040.48 %). 
These drugs also showed the highest variation of maximum price 
from average price (278 and 227.87 % respectively). The relatively 
cheapest brand (largest variation of minimum price from average) 
was Atorvastatin 10 mg tab-also having the highest numbers of 58 
brands listed. 
  
Table 1: Brand-Price variation in cardiovascular drug formulations under DPCO 
















 % var. 
from 
avg. 










72.85 565.3 2.28 




27.31 113.1 4.11 




56.85 214.17 3.73 




57.08 202.54 5.54 




45.07 156.82 1.96 




42.17 145.6 3.27 




64.68 671.93 1.97 




71.25 1040.58 3.13 




54.25 275.83 2.76 




48.79 282.86 4.75 




73.84 665.55 4.22 




78.8 770.83 6.74 








19.81 47.56 2245.83 




78.6 1067.5 11.07 
Isosorbide 
mononitrate 




26.45 78.1 2.12 




45.16 153.65 3.63 




18.96 53.9 2.5 
Abbreviations: avg. = average, var. = variation, max. = maximum, min. = minimum 
 
We observed 15 drugs in 28 formulations among the 
antibacterials [table 2, 3]. 24 formulations showed more than a 
100 % price variation between maximum and minimum priced 
brands. Largest variation was shown by ethambutol 400 mg tab 
(480.28 %) followed by cefixime 200 mg tab (389.9 %). The 
highest variations from average price were shown by 
amoxicillin+clavulanic acid 625 mg tab and ethambutol 400 mg 
tab (111.7 % and 98 % respectively). The former also had 
maximum 90 brands available, followed by azithromycin 500 mg 
injection with 83 brands. 
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Table 2: Brand-Price variation in beta-lactam antibacterial drug formulations under DPCO 















 % var. 
from avg. 
 % var.  
between max. 
and min. 
 DPCO c 
ceiling p 
price 
Amoxicillin 250 mg  
Cap 




26 157.65 3.04 
 500 mg  
Cap 




20.2 113.2 6.72 
Ampicillin 250 mg  
Cap 




43.9 166.09 2.76 
 500 mg  
Cap 




44.1 176.23 5.24 
 500 mg  
Inj 




57.2 253.77 14.8 
Cefotaxime 250 mg  
Inj 




30 114.31 15.77 
 500 mg  
Inj 




36.2 148.06 20.82 
Ceftazidime 1 g  
inj 




29.4 105.02 253.05 
Ceftriaxone  250 mg  
inj 




27.7 129.18 27.16 
 1 g 
inj 




32.8 167.09 61.21 
Cephalexin 250 mg  
Cap 




26.5 86.89 5.79 
 500 mg 
cap 








625 mg  
Tab 





56 379.79 24.80 
 
 1.2 g 
inj 






60 263.38 140.63 
Cefixime 100 mg  
Tab 




51.28 175 8.49 
 200 mg  
Tab 




61.57 389.9 12.42 
 
Table 3: Brand-Price variation in antibacterial drug formulations (other than beta-lactam) under DPCO 















 % var. 
from avg. 






Vancomycin 500 mg  
Inj 




25.7 55.6 365.02 
Amikacin  250 mg/2 ml 
Inj 




20.5 117.24 15.41 
Azithromycin 100 mg  
Tab 




23.3 48.3 5.66 
 250 mg  
Tab 




43.7 176.15 11.33 
 500 mg  
Inj 




37 157.19 22.65 
Ciprofloxacin 250 mg  
Tab 




27.6 134.97 2.1 
 500 mg  
Tab 




35.6 173.85 4.01 
 200 mg/ 
100 ml Inj 




43.2  200 0.27 
Ethambutol  400 mg  
Tab 




65.8 480.28 2.4 
 800 mg  
Tab 




60.5 227.2 4.13 
Rifampicin 450 mg  
Cap 







Gentamicin 40 mg/ml  
Inj 




4.45 11.23 2.41 
 
Among the drug formulations for analgesia-inflammation, asthma, 
diabetes, arthritis (table–4), 15 drug formulations were observed. 
Seven of these showed more than a 200 % price variation between 
maximum and minimum priced brands. The largest variation was 
seen with diclofenac 25 mg/ml injection (2060.8 %) which also 
showed maximum variation from average price (356.7 %). The 
relatively cheapest brand was paracetamol 500 mg tab (113.2 %). 
Diclofenac 25 mg/ml injection had the maximum brands listed (22). 
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Table 4: Brand-Price variation in miscellaneous drug formulations under DPCO 
















 % var. 
from 
avg. 






Insulin 40 IU/ml 
Inj 





8 12.7  
Metformin 500 mg  
Tab 




49.1 210.07 1.72 
Diclofenac 50 mg  
Tab 




57.2 303.27 2.15 
 25 mg/ml  
Inj 




76 2060.8 1.64 
 
Paracetamol 500 mg  
Tab 




113.2 227.86 1.04 
Tramadol 50 mg  
Cap 




15.66 45.23 6.66 
 50 mg/ml  
Inj 




47.1 164.33 12.95 
Allopurinol 100 mg  
Tab 




42 157.93 2.31 
 Leflunomide 10 mg  
Tab 




19.3 62.5 16.67 
 20 mg  
Tab 




15.2 46.5 31.61 
Hydroxy-
chloroquine 
200 mg  
Tab 




38.7 44.72 6.23 
Salbutamol 2 mg  
Tab 




53.2 228 0.16 
 4 mg  
Tab 




54 259.75 0.19 
Dexametha- 
sone 
0.5 mg  
Tab 




6.25 28.57 0.21 
We also found that a number of the highest priced brands had prices above the fixed ceiling prices, substantially so in some cases. 
 
DISCUSSION 
The results clearly indicate that despite the measure of price control 
in India, significant inter-brand price variations still exist in the 
pharmaceutical market. The DPCO was expected to bring down or 
even eliminate such inter-brand price variations, but it has not 
achieved its objective completely. Huge inter-brand price differences 
in the marketing of branded generics are indicative of a severe 
market failure, as recognized by the NPPA itself [18]. 
Magnitude and significance of price variation  
Such large brand price variation in the ‘price controlled’ essential 
drugs is alarming, with prices of the most expensive brands being 
upwards of 100–200 % from average for many commonly used 
drugs. In some cases, the costliest brands are more than 1000 % 
expensive than the cheapest brands. These variations are 
comparable to the brand price variations in previous studies [16-17] 
conducted before the DPCO came to effect in 2013. This means that 
current price control mechanisms haven’t been successful in 
bringing down the brand price variations effectively. An expensive 
brand can cost a patient more than 10 times a cheaper brand and 2 
times the average price. It is a grave state in the context of India 
where health insurance is still an alien concept, and 50-90 % of the 
medicine cost is borne by the patient [19-21]. 
The consequences of this unwarranted expenditure become more 
severe in the management of chronic diseases like hypertension, 
dyslipidaemia, arthritis, tuberculosis, diabetes. The brand price 
differences can run into huge numbers with therapy required for 
years or even lifetime. For example, the highest consumption of 
antibiotics in the world is seen in India (13 billion standard units per 
year) [22], the average cost of monthly single drug therapy for 
hypertension is estimated to be 1.8 times the day's wages (average) 
with every 3rd individual over 18 now supposedly having 
hypertension [23-24], the average direct annual costs per diabetic 
patient is around Rs. 15000 and rises up to four times with 
complications [25] whereas the same has been found to be up to 
$598 for asthma [26]. Clearly, these illnesses create a substantial 
financial burden and can result in a compromise on diagnosis and 
treatment with affordability suffering further with polypharmacy.  
It is also difficult to understand how some brand prices are still 
above ceiling prices. Could this be due to non update or revision of 
prices by companies or due to the addition of local taxes? We noted 
ceiling prices which became effective from 1st April 2015 [3, 27]. The 
CIMS prices are from July onwards, so the 45 d grace period 
provided in the DPCO for revision of prices had passed. This poses a 
question mark on the measures being taken by the government for 
active surveillance to implement price control. 
Possible reasons for price variations 
One of the primary reasons for brand price variation in Indian 
pharmaceutical market is the very nature and composition of 
pharma sector in India which is predominantly a branded generic 
market i.e. multiple companies sell a particular drug under different 
brand names. Hence, the number of brands available in the market is 
very high: 60,000-70,000 [28]. Similarly, factors like the asymmetry 
of information or imperfect information, government regulations 
and pricing policies, costs of raw supplies, distribution and 
promotion, economic goals of the parent company, target return on 
investment also contribute to this phenomenon [29-32]. 
Doctors usually end up prescribing more widely endorsed and 
meticulously marketed brands to the patients not keeping in mind the 
cost of the drug. Patients may be non-compliant to the costly brands or 
reduce doses taken in order to save money. A sizable part of the 
company’s marketing including the continuing medical education 
activities (CMEs), is spent on inappropriately persuading doctors to 
prescribe their drugs [33]. Pharmacists also dispense the most 
expensive brands for higher profit margin. They may also have tie up 
with particular companies, selectively stocking only their products.  
Price variations in context of the current pricing policy 
The DPCO is a welcome initiative by the government aimed at 
checking the rising drug prices. But there seems to be a fault in the 
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design and implementation of the order. The pricing policy needs to 
be scrutinised, as rightly pointed out by the honourable Supreme 
Court, [8] taking cognizance of the fact that generic drugs are being 
made available by governments of Kerala, Tamil Nadu at costs up to 
4000 % lesser than the ceiling prices! 
The current pricing policy is a market based policy whereby ceiling 
prices are determined by simply averaging the prices of brands of all 
companies which have a market share greater than 1 %, plus an 
additional margin of 16 % to the retailer [3]. There is also the 
provision of extra addition of local taxes to this cost. So, in effect, the 
ceiling prices are actually influenced by the already existing prices of 
popular brands in the market. A much better alternative would be 
adopting the cost of manufacture based formula used in the old 
pricing policy (DPCO 1995). It stated that the retail price of a 
formulation shall be calculated by the Government in accordance 
with the following formula namely: [34] 
R. P. = (M. C.+C. C.+P. M.+P. C.) x (1+MAPE/100)+ED. 
where M. C. means material cost, C. C. means conversion cost, P. M. 
means the cost of the packing material, P. C. means packing charges; 
MAPE means Maximum Allowable Post-manufacturing Expenses; ED 
means excise duty. 
As is evident, in this formula the material cost, conversion cost, cost 
of packing material/charges, post-manufacturing expenses, excise 
duty were all taken into account to determine ceiling prices. It would 
be highly recommended to use this formula for an improved pricing 
policy; whereby the government finds out what is the actual cost of 
manufacture of a particular drug and then provides a reasonable 
margin to the manufacturer/retailer over it. It might bring down the 
ceiling prices sufficiently to disallow the unfairly high pricing of 
brands. Currently, it seems that ceiling prices themselves are too 
high which is contributing to the extensive brand price variation.  
Varying brand prices-Is it an issue of quality? 
Questions are often raised regarding the quality of the so called 
cheaper brands. Ideally, all drug manufacturers have to follow the 
Good Manufacturing Practices (GMP) norms laid out in the schedule 
M of the Drugs & Cosmetics Act 1945. GMP covers all aspects of 
production quality and standards-raw materials, premises, 
equipment, training and personal hygiene of the staff and involves a 
stringent verification process before the issue of a GMP certificate to 
a drug manufacturer [35]. 
But the reality seems to be different. As noted in a recent review, 
probably 12-25 % of the medicines supplied globally from India is 
contaminated, substandard and counterfeit [36]. As per World 
Health Organization, poor quality drugs are the spurious/falsely-
labelled/falsified/counterfeit (SFFC) drugs that can cause treatment 
failure or even death [37] and 75 % of the global cases of SFFC 
medicines originate from India [38]. The Central Drugs Standard 
Control Organization (CDSCO) has categorised such drugs as not of 
standard quality (NSQ) products. A recent study, aiming to know the 
correct extent of the SFFC or NSQ drugs in India, found that quality 
control mechanisms in place for manufacture and sale drugs in India 
are not good enough. While official data from several studies 
suggested presence of 3–12 % drugs of spurious and/or 
substandard quality drugs, data from Indian media suggests this to 
be in the region of 30–40 % [39]. Recently, Indian generics of 
reputed companies have also come under US Food and Drug 
Administration (FDA) scanner for quality related issues due to 
violations in manufacturing processes [40].  
This suggests an absence of stringent enforcement of the rules and 
regulations or possible corrupt practices in local FDAs. There is a 
reported shortage of drug inspectors for regular vigilance over 
manufacturing units and distribution outlets [41]. The incidence of 
death of numerous women is reportedly consuming ciprofloxacin 
tablets mixed with zinc phosphide–a rat poison, in Raipur, 
Chhattisgarh shows there are serious issues related to adherence to 
drug manufacturing standards by small-scale manufacturers [42].  
Technically, all brands need to be bioequivalent which means their 
plasma level profiles should be comparable and super imposable 
within prescribed limits (80–125 %) [43]. This bioequivalence may 
differ significantly due to inadequate BE studies by smaller firms. In 
the case of drugs like phenytoin, warfarin, digoxin that show a steep 
dose response curve, even a slight difference in bioavailability of 
different brands can cause serious adverse effects. Similarly, drugs 
having a narrow margin of safety like antiarrhythmics, theophylline, 
and adrenal steroids may be affected too [43]. The inadequate 
bioequivalence may also translate into a loss of therapeutic 
effectiveness.  
Thus the question of ‘branded generics’, available as so-called 
cheaper alternatives to the strictly branded drugs (which are actual 
innovator products) becomes a sensitive issue to address. In India, 
almost all medicines in India are sold under a brand/trade name and 
may be branded medicines or branded-generic (simply called 
generics worldwide). Actually, there are very few branded medicines 
in the Indian market as till January 2005 product patent was not 
applicable in India; most drugs are in fact generics with a brand 
name! Many pharmaceutical companies manufacture two types of 
products for the same molecule, i.e. the branded product which they 
advertise and push through doctors and branded-generic which are 
expected to be pushed by retailers. The so-called branded medicines 
are manufactured and promoted by reputed multinationals or Indian 
manufacturers. Although the generic medicines are bio-equivalents 
of their innovator counterparts, these are widely believed as inferior 
in their therapeutic efficacy and quality to branded products. A study 
comparing these two versions of drugs has indicated that both the 
branded and branded-generic versions of the medicines had identical 
quality, and they fulfilled all the criteria prescribed by the statutory 
standards [44].  
Some studies have revealed retailer margins for the branded generics 
are very large (200-1000 %) compared to branded drugs (25-30 %). 
Pharmaceutical companies decide the final price (MRP) to the patient 
aw ell as the margins for the retailer. If the marketing and promotion 
are done by the retailer as in the case of branded-generic then the Price 
To Retailer is less, but MRP is not much different. Therefore, the 
ultimate consumer, i.e. patient is not benefited much by 
preferring branded-generic versions to its branded version. The huge 
profit margins for retailers ranging from 500 % to1000 % on generic 
medicines in India have been reported [45].  
Use of good quality generic drugs, which are bioequivalent to brand 
name drug, can help contain prescription drug spending. The 
government of India has opened few generic drug stores in some 
states that sell generic medicines manufactured by public sector 
companies [46]. The quality of generic medicines available on these 
stores at cheaper rates should be tested and compared with popular 
brands, and results should be widely published. 
Suitable changes in the drug price policy may be made to have lower 
prices for branded-generic versions. Transparency in fixing the MRP 
by the manufacturer and clear guidelines for markups at least 
for branded-generics is also recommended. 
Scope of DPCO–need for improvement 
Firstly, the NLEM needs to be revised, to allow inclusion of a wider 
spectrum of drugs in the DPCO. Many newer and commonly used 
drugs in a current scenario like anticancer, antimicrobial, 
antidiabetic, organ transplantation drugs need to be included in the 
NLEM [47]. More drug combinations need to be covered in the 
NLEM, as they account for almost 45 % of the total pharma market 
[48]. A number of pharma companies have also started 
circumventing the provisions of DPCO by changing the composition 
and strength of formulations to evade price control as well as 
introducing the ‘me too’ drugs which are similar to each other in 
structure and offer an only marginal advantage over existing 
treatment [49]. This practice needs to be curbed. The government 
should also use its special authority to cap the prices of non-
scheduled drugs (not in the NLEM), by citing them to be in the public 
interest [18].In accordance with this provision, the NPPA had 
ordered capping of prices of 108 non-essential drugs in July 2014, 
including important cardiovascular and antidiabetic medicines [10-
11]. But there was intense industry opposition to this move from the 
industry [50]. The government subsequently withdrew the earlier 
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guidelines in September 2014, essentially ending the NPPA’s power 
to bring non-scheduled formulations under price control [51]. With 
the implementation of DPCO, only 13 % of the total Indian 
pharmaceutical market has actually come under price control out. So 
the brand price variation in the non-price controlled market can be 
deemed to be even bigger.  
Another suggestion to check high pricing of drugs could be the 
provision of incentives to drug manufacturers through other means 
like tax benefits (similar to orphan drugs).  
Expanding health insurance 
A different approach could be introducing a comprehensive health 
insurance system, with the government purchasing bulk volume of 
drugs from manufacturers to ensure that industry also receives its 
fair profit margin akin to the systems employed by the U. S. and U. K. 
[52]. Studies have also shown that providing a manual of 
comparative drug prices annotated with prescribing advice to 
physicians reduced their patient’s drug expense [53]. 
CONCLUSION 
Given the magnitude of inter-brand price variations observed among 
the drugs under price control and the detrimental impact it has on 
patient’s financial resources, we strongly recommend that the 
government authorities need to revise their pricing policies and 
ensure regulatory checks to bring all brand prices within ceiling 
prices. There is ample scope for significant reduction in NPPA ceiling 
prices. There should be an expansion of the list of essential 
medicines. There should be strict adherence to the GMP norms in 
drug manufacture. There is a moral obligation at the level of 
healthcare professionals too, especially physicians, to keep drug 
prices in mind while prescribing drugs to patients. On a positive 
note, more drugs have been notified for price control recently, and 
there has been a decline in a number of poor quality drugs cases. But 
it is imperative that this matter be considered and monitored 
vigorously to safeguard the interests of the patient community.  
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